

## State of Oklahoma SoonerCare

## Turalio<sup>™</sup> (Pexidartinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy billing (NDC:	) Start Date (or date of next dose):	
Dose:	Regimen:	
Pharmacy Information		
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	_ Prescriber Fax:	Specialty:
<b>Criteria</b>		
□ Soft Tissue Sarcoma – Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor  A. Is member a candidate for surgery? Yes No  B. Will pexidartinib be used as a single-agent? Yes No  □ Other, please provide diagnosis:  Additional Information:		
For Continued Authorization:  1. Date of last dose:  2. Does member have any evidence  3. Has member experienced adverse If yes, please specify adverse reaction Additional Information:	e of progressive disease while of edug reactions related to pex	kidartinib therapy? Yes No
Prescriber Signature:  I certify that the indicated treatment	nt is medically necessary and	Date: d all information is true and correct to the

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

## PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-132 6/6/2024